Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VIRI Stock Summary
In the News
Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript
Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Duncan - CEO Angela Walsh - SVP, Finance & Treasurer Mike Gendreau - CMO Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update.
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets. Management will also host a webcast and conference call on November 13, 2023 at 8:30 a.m. ET to discuss the results and provide a corporate update.
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY.
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.
Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript
Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Angela Walsh - Senior Vice President, Finance & Treasurer Greg Duncan - Chief Executive Officer Mike Gendreau - Chief Medical Officer Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Q2 2023 Earnings Update.
VIRI Stock Earnings: Virios Beats EPS Estimates
Virios Therapeutics (NASDAQ: VIRI ) reported first quarter results for 2023. Virios reported a loss per share of 8 cents.
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets.
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune response-triggered maladies. The company went public in December 2020.
Virios Therapeutics stock doubles as fibromyalgia program moves forward
Virios Therapeutics shares more than doubled after the biotechnology company announced that its proposed Phase 3 program featuring its lead development candidate IMC-1 for fibromyalgia has been considered acceptable based on initial feedback from the US Food and Drug Administration (FDA). IMC-1 is a novel, fixed-dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the company's end goal being the reduction of virally promoted fibromyalgia disease symptoms.
Why Is Virios Therapeutics (VIRI) Stock Up 92% Today?
Virios Therapeutics (NASDAQ: VIRI ) stock is rocketing higher on Tuesday following an update on its planned Phase 3 clinical trial of IMC-1. IMC-1 is Virios Therapeutics' lead drug candidate in development for the treatment of herpes virus replication.
VIRI Financial details
VIRI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.57 | -2.1 | -1.92 | -1.1 | -0.28 | |
Operating cash flow per share | -0.43 | -0.79 | -1.88 | -1.04 | -0.26 | |
Free cash flow per share | -0.43 | -0.79 | -1.88 | -1.04 | -0.26 | |
Cash per share | 0.06 | 6.05 | 1.68 | 0.64 | 0.18 | |
Book value per share | -1.02 | 6.08 | 1.74 | 0.66 | 0.2 | |
Tangible book value per share | -1.02 | 6.08 | 1.74 | 0.66 | 0.2 | |
Share holders equity per share | -1.02 | 6.08 | 1.74 | 0.66 | 0.2 | |
Interest debt per share | 0.81 | 0.08 | 0 | -0.01 | 0 | |
Market cap | 80.75M | 37M | 42.65M | 2.61M | 10.8M | |
Enterprise value | 84.08M | 7.21M | 28.64M | -4.42M | 7.48M | |
P/E ratio | -29.17 | -3.58 | -2.67 | -0.21 | -2.04 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -38.6 | -9.5 | -2.72 | -0.23 | -2.22 | |
PFCF ratio | -38.6 | -9.5 | -2.72 | -0.23 | -2.22 | |
P/B Ratio | -16.34 | 1.24 | 2.94 | 0.36 | 2.84 | |
PTB ratio | -16.34 | 1.24 | 2.94 | 0.36 | 2.84 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -38.59 | -0.72 | -1.83 | 0.36 | -1.37 | |
EV to operating cash flow | -40.19 | -1.85 | -1.83 | 0.39 | -1.54 | |
EV to free cash flow | -40.19 | -1.85 | -1.83 | 0.39 | -1.54 | |
Earnings yield | -0.03 | -0.28 | -0.37 | -4.66 | -0.49 | |
Free cash flow yield | -0.03 | -0.11 | -0.37 | -4.39 | -0.45 | |
Debt to equity | -0.74 | 0 | 0 | 0 | 0 | |
Debt to assets | 11.51 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -1.53 | 2.98 | 0.9 | 0.57 | 0.61 | |
Current ratio | 0.19 | 20.55 | 12.37 | 8.02 | 11.62 | |
Interest coverage | -7.38 | -26.04 | -2.76K | 182.52 | 0 | |
Income quality | 0.85 | 0.38 | 0.98 | 0.94 | 0.92 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.01 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.63 | 16.94 | 8.66 | 4.05 | 1.13 | |
ROIC | 1.87 | -0.33 | -1.08 | -1.67 | -1.43 | |
Return on tangible assets | -8.76 | -0.33 | -1.01 | -1.46 | -1.27 | |
Graham Net | -1.02 | 5.74 | 1.53 | 0.54 | 0.16 | |
Working capital | -1.3M | 29.94M | 14.5M | 7.33M | 3.81M | |
Tangible asset value | -4.94M | 29.94M | 14.5M | 7.33M | 3.81M | |
Net current asset value | -4.94M | 29.94M | 14.5M | 7.33M | 3.81M | |
Invested capital | -0.74 | 0 | 0 | 0 | 0 | |
Average receivables | 559.5 | 554.5 | 162 | 0 | 0 | |
Average payables | 90.54K | 202.16K | 361.38K | 463.51K | 342.54K | |
Average inventory | -392.5 | -554.5 | -162 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.56 | -0.35 | -1.1 | -1.66 | -1.39 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.11 | -0.08 | -0.08 | -0.06 | -0.06 | |
Operating cash flow per share | -0.15 | -0.09 | -0.04 | -0.05 | -0.08 | |
Free cash flow per share | -0.15 | -0.09 | -0.04 | -0.05 | -0.08 | |
Cash per share | 0.38 | 0.29 | 0.25 | 0.25 | 0.17 | |
Book value per share | 0.4 | 0.33 | 0.25 | 0.25 | 0.2 | |
Tangible book value per share | 0.4 | 0.33 | 0.25 | 0.25 | 0.2 | |
Share holders equity per share | 0.4 | 0.33 | 0.25 | 0.25 | 0.2 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 4.33M | 6.75M | 25.41M | 17.66M | 11.07M | |
Enterprise value | -2.71M | 1.41M | 20.82M | 12.87M | 7.76M | |
P/E ratio | -0.53 | -1.14 | -4.41 | -3.57 | -2.51 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -1.62 | -3.97 | -34.22 | -18.38 | -7.54 | |
PFCF ratio | -1.62 | -3.97 | -34.22 | -18.38 | -7.54 | |
P/B Ratio | 0.59 | 1.13 | 5.42 | 3.71 | 2.91 | |
PTB ratio | 0.59 | 1.13 | 5.42 | 3.71 | 2.91 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 1.29 | -0.91 | -14.09 | -10.1 | -6.82 | |
EV to operating cash flow | 1.01 | -0.83 | -28.04 | -13.4 | -5.28 | |
EV to free cash flow | 1.01 | -0.83 | -28.04 | -13.4 | -5.28 | |
Earnings yield | -0.47 | -0.22 | -0.06 | -0.07 | -0.1 | |
Free cash flow yield | -0.62 | -0.25 | -0.03 | -0.05 | -0.13 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 3.36 | 3.42 | 3.11 | 3.76 | 2.91 | |
Current ratio | 8.02 | 9.71 | 8.83 | 10.77 | 11.62 | |
Interest coverage | 93.65 | 38.52 | 0 | 0 | -28.16 | |
Income quality | 1.31 | 1.12 | 0.52 | 0.78 | 1.33 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1 | 0.77 | 0.67 | 0.6 | 0.5 | |
ROIC | -0.28 | -0.25 | -0.31 | -0.27 | -0.31 | |
Return on tangible assets | -0.24 | -0.23 | -0.28 | -0.24 | -0.26 | |
Graham Net | 0.33 | 0.26 | 0.22 | 0.23 | 0.15 | |
Working capital | 7.33M | 4.78M | 4.07M | 4.76M | 3.81M | |
Tangible asset value | 7.33M | 5.97M | 4.69M | 4.76M | 3.81M | |
Net current asset value | 7.33M | 4.78M | 4.07M | 4.76M | 3.81M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 626.29K | 354.13K | 174.7K | 209.84K | 158.64K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.28 | -0.25 | -0.31 | -0.26 | -0.29 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
VIRI Frequently Asked Questions
What is Virios Therapeutics, Inc. stock symbol ?
Virios Therapeutics, Inc. is a US stock , located in Alpharetta of Ga and trading under the symbol VIRI
What is Virios Therapeutics, Inc. stock quote today ?
Virios Therapeutics, Inc. stock price is $0.4791 today.
Is Virios Therapeutics, Inc. stock public?
Yes, Virios Therapeutics, Inc. is a publicly traded company.